Amit Govil

Amit Govil serves as Chief Technology Officer at Isto Biologics (Formerly Arteriocyte). Isto Biologics (Formerly Arteriocyte) operates in the medical devices sector with approximately 150.0 employees. The company is headquartered in Carlsbad, California. Isto Biologics (Formerly Arteriocyte) generates annual revenue of 13000000.0. To date, Isto Biologics (Formerly Arteriocyte) has raised 12710082.0 in total funding, with the most recent round being Other.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 13,743 executive contacts are available in California.
• • Our database includes 201,469 c suite-level executives.

Salesforce SparkPost Outlook Amazon AWS Rackspace Email Google Tag Manager Mobile Friendly Hubspot Google Analytics Google Font API Varnish Wix Apache Ubuntu Remote SAP IoT Viewpoint AI Outlook Rackspace Email Amazon AWS Salesforce SparkPost Ubuntu Apache Wix Mobile Friendly Google Tag Manager Varnish Google Font API Google Analytics Hubspot SAP Viewpoint Remote AI IoT

orthobiologics medical device products for spine & orthopedics bone grafts celltherapy regenerative medicine minimally invasive spine & orthopedic solutions spinal disc regeneration platelet rich plasma biotechnology life sciences medical equipment manufacturing autologous therapies concentrated bone marrow aspirate platelet poor plasma magellan system bone grafting solutions allografts influx products fibrant proteios sparc plus sponge synthetics inqu lightning needle aspiration needle clinical operations patient recovery tissue regeneration cell concentration therapeutic solutions healing technologies surgeon support customized solutions biologics biosynthetic bone grafts clinical efficacy growth factors bone healing patient-centric care in-hospital use biosynthetic solutions flexibility in grafting closed-loop design biocompatible materials human tissue engineering pure human bone grafts demineralized bone matrix integrative bone matrix cell-friendly products functional allografts advanced biomaterials rapid recovery point of care therapy cost-effective treatment enhanced osteoconductive properties customized output volumes bone regeneration hospital & health care medical devices

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Amit Govil in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Isto Biologics (Formerly Arteriocyte).

How do I reach Amit Govil directly?

Amit Govil's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Technology Officer at Isto Biologics (Formerly Arteriocyte). Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Amit Govil work for?

Amit Govil is Chief Technology Officer at Isto Biologics (Formerly Arteriocyte), a company in the medical devices sector with 150.0 employees. The company is based in Carlsbad, California.

Can I pitch or sell to Amit Govil?

As Chief Technology Officer at Isto Biologics (Formerly Arteriocyte), Amit Govil is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Amit Govil directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Amit Govil in?

Amit Govil works in the medical devices industry as Chief Technology Officer at Isto Biologics (Formerly Arteriocyte). MessageCEO provides verified contact information for executives across all major industries.

Is Amit Govil's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Amit Govil's profile is kept up-to-date with the latest available information.

Last updated: May 13, 2026